- Lobbying
- cubist AND pharmaceuticals
Lobbying Arrangements Results for 'Cubist Pharmaceuticals'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details General pharmaceutical issues |
Cubist Pharmaceuticals, Inc.
Pharmaceutical company |
Capitol Hill Consulting Group | |||
Details Medicare reimbursement and issues related to the GAIN Act |
Cubist Pharmaceuticals
|
Subject Matter (fka Elmendorf Ryan) | |||
Details Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM)Act; Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of r... |
Cubist Pharmaceuticals, Inc.
|
in-house lobbying | |||
Details Medicare In-Patient Hospital Payment Procedures. |
Cubist Pharmaceuticals, Inc.
|
PATTON BOGGS LLP | |||
Details General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; H.R. 6331, the Generating Antibiotic Incentives Now (GAIN)... |
Cubist Pharmaceuticals Inc.
|
East End Group, LLC. | |||
Details Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints Antibiotic resistance Reimbursement issues for an... |
Cubist Pharmaceuticals, Inc.
|
Avenue Solutions | |||
Details Implementation of the Affordable Care Act of 2010 (Pub. L. 111-148) Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safet... |
CUBIST PHARMACEUTICALS
|
FOLEY HOAG LLP | |||
Details Issues related to antibiotics and breakpoints. Issues related to Medicare reimbursement of antibiotics; H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms. |
Cubist Pharmaceuticals, Inc.
|
THE NICKLES GROUP, LLC | |||
Details FY 2014 Omnibus HR 3547 FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67 FY 2015 Budget, H Con Res 96 (no Senate Companion at this time) HJ... |
Cubist Pharmaceuticals, Inc.
|
SLC Health Strategies, LLC | |||
Details S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672... |
America's Specialty Medicine Companies
|
Constantine Cannon, LLP | |||
Details H. Con. Res 112, Establishing the budget for the US Government for FY 2013 (Medicare-related provisions - antibiotic resistance). H.R. 5973 / S. 2375, Agriculture, Rural Development, Food and Drug ... |
Cubist Pharmaceuticals, Inc.
|
PODESTA GROUP, INC. |